The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.
Abstract
Background/Aims: The purpose of this study was to determine the correlations between inflammatory factors—including absolute lymphocyte count, lactate dehydrogenase, β2-microglobulin, albumin, C-reactive protein, and ferritin—and the prognosis for survival in patients with multiple myeloma (MM) treated with induction chemotherapy containing thalidomide and who underwent autologous stem cell transplantation (ASCT). Methods: Data from patients at 13 university hospitals in South Korea were collected retrospectively between December 2005 and May 2013. Results: The median age of the 232 patients was 57 years (range, 33 to 77) and the male to female ratio was 1.09:1. In the multivariate analysis, fewer than two combined abnormal inflammatory factors was the only independent prognostic factor for superior progression-free survival (relative risk [RR], 0.618; 95% confidence interval [CI], 0.409 to 0.933; p = 0.022), and platelet count > 100 × 109/L and fewer than two combined abnormal inflammatory factors were independent prognostic factors for superior overall survival (RR, 4.739; 95% CI, 1.897 to 11.839; p = 0.001 and RR, 0.263; 95% CI, 0.113 to 0.612; p = 0.002, respectively). Conclusions: Patients with two or more than two combined inflammatory factors who were treated with thalidomide induction chemotherapy and who underwent ASCT showed significantly shorter survival compared to those with fewer than two combined inflammatory factors. These results could be helpful for predicting prognosis in patients with MM.
참고문헌 (29)
- Palumbo A, "Thalidomide for treatment of multiple myeloma: 10 years later", Blood, 111, pp.3968~3977 (2008)
- Cavo M, "Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stemcell transplantation in newly diagnosed multiple myeloma:a randomised phase 3 study", Lancet, 376, pp.2075~2085 (2010)
- Morgan GJ, "Role of thalidomide in the treatment of patients with multiple myeloma", Crit Rev Oncol Hematol, 88(Suppl 1), pp.S14~S22 (2013)
- Moreau P, "Initial treatment of transplant candidates with multiple myeloma", Semin Oncol, 40, pp.585~591 (2013)
- Ozaki S, "Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future", Biomed Res Int, 2014, pp.394792~ (2014)
- Ahn SY, "Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study", Ann Hematol, 93, pp.1571~1577 (2014)
- Minarik J, "10 Years of experience with thalidomide in multiple myeloma patients: report of the Czech Myeloma Group", Leuk Res, 37, pp.1063~1069 (2013)
- Vande Broek I, "Continuous treatment in multiple myeloma: the future?", Transfus Apher Sci, 49, pp.147~150 (2013)
- Lokhorst HM, "Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma", Haematologica, 93, pp.124~127 (2008)
- Copur S, "Lactate dehydrogenase and its isoenzymes in serum from patients with multiple myeloma", Clin Chem, 35, pp.1968~1970 (1989)
- Engelhardt M, "European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma", Haematologica, 99, pp.232~242 (2014)
- Kyrtsonis MC, "Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma", Semin Hematol, 46, pp.110~117 (2009)
- Bataille R, "C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system", Blood, 80, pp.733~737 (1992)
- Kyrtsonis MC, "Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma", Br J Haematol, 137, pp.240~243 (2007)
- Strasser-Weippl K, "Ferritin as prognostic marker in multiple myeloma patients undergoing autologous transplantation", Leuk Lymphoma, 55, pp.2520~2524 (2014)
- Ege H, "Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study", Br J Haematol, 141, pp.792~798 (2008)
- Greipp PR, "International staging system for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)
- Durie BG, "A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival", Cancer, 36, pp.842~854 (1975)
- Lim JH, "Cytogenetic classification in Korean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities", Eur J Haematol, 92, pp.313~320 (2014)
- Palumbo A, "International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation", J Clin Oncol, 32, pp.587~600 (2014)
- Mikhael JR, "Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013", Mayo Clin Proc, 88, pp.360~376 (2013)
- Rajkumar SV., "Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management", Am J Hematol, 88, pp.226~235 (2013)
- Oh S, "Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study", Ann Hematol, 93, pp.1353~1361 (2014)
- Cavo M, "International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation", Blood, 117, pp.6063~6073 (2011)
- Barlogie B, "Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival", Ann Hematol, 90, pp.423~428 (2011)
- Kim JE, "Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma", Ann Hematol, 89, pp.391~397 (2010)
- Bataille R, "Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias", J Clin Invest, 84, pp.2008~2011 (1989)
- Papadaki H, "Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity", Acta Haematol, 97, pp.191~195 (1997)
- Lauta VM., "A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications", Cancer, 97, pp.2440~2452 (2003)